Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 278

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Current strategies in extending half-lives of therapeutic proteins

Zaman, Rahela, Islam, Rowshan Ara, Ibnat, Nabilah, Othman, Iekhsan, Zaini, Anuar, Lee, Chooi Yeng, Chowdhury, Ezharul Hoque·2019·Journal of Controlled Release

Abstract

ABSTRACT Macromolecular protein and peptide therapeutics have been proven to be effective in treating critical human diseases precisely. Thanks to biotechnological advancement, a huge number of proteins and peptide therapeutics were made their way to pharmaceutical market in past few decades. However, one of the biggest challenges to be addressed for protein therapeutics during clinical application is their fast degradation in serum and quick elimination owing to enzymatic degradation, renal clearance, liver metabolism and immunogenicity, attributing to the short half‐lives. Size and hydrophobicity of protein molecules make them prone to kidney filtration and liver metabolism. On the other hand, proteasomes responsible for protein destruction possess the capability of specifically recognizing almost all kinds of foreign proteins while avoiding any unwanted destruction of cellular components. At present almost all protein‐based drug formulations available in market are administered intravenously (IV) or subcutaneously (SC) with high dosing at frequent interval, eventually creating dose‐fluctuation‐related complications and reducing patient compliance vastly. Therefore, artificially increasing the therapeutic half‐life of a protein by attaching to it a molecule that increases the overall size (eg, PEG) or helps with receptor mediated recycling (eg, albumin), or manipulating amino acid chain in a way that makes it more prone towards aggregate formation, are some of the revolutionary approaches to avoid the fast degradation in vivo. Half‐life extension technologies that are capable of dramatically enhancing half‐lives of proteins in circulation (2–100 folds) and thus improving their overall pharmacokinetic (PK) parameters have been successfully applied on a wide range of protein therapeutics from hormones and enzymes, growth factor, clotting factor to interferon. The focus of the review is to assess the technological advancements made so far in enhancing circulatory half‐lives and improving therapeutic potency of proteins. Graphical abstract Figure. No Caption available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2019.02.016

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Cited by

See all 278

Metadata

Authors
Zaman, R., Islam, R. A., Ibnat, N., Othman, I., Zaini, A., Lee, C. Y., & Chowdhury, E. H.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2019-05
Volume
301
Pages
176-189
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2920526722
Cited by
278
References
79
FWCI
6.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current strategies in extending half-lives of therapeutic proteins. https://app.cochat.ai/papers/10.1016/j.jconrel.2019.02.016
The paper
Zaman, R., Islam, R. A., Ibnat, N., Othman, I., Zaini, A., Lee, C. Y., & Chowdhury, E. H. (2019). Current strategies in extending half-lives of therapeutic proteins. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2019.02.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.